Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 6, 2026, 9:59 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 176 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Partial Seizures Clear all

Conditions: Epilepsy, Partial
Interventions: lamotrigine, 300 mg/day, lamotrigine, 250 mg/day; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 13 Years and older
Enrollment: 226 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2008
U.S. locations: 67
States / cities: Alabaster, Alabama • Litchfield Park, Arizona • Mesa, Arizona + 56 more

Conditions: Refractory Partial Seizures
Interventions: E2007 (perampanel), Placebo; Drug
Lead sponsor: Eisai Inc.; Industry
Eligibility: 12 Years and older
Enrollment: 389 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2011
U.S. locations: 32
States / cities: Huntsville, Alabama • Phoenix, Arizona • Tucson, Arizona + 17 more

Conditions: Epilepsy
Interventions: pregabalin; Drug
Lead sponsor: Pfizer's Upjohn has merged with Mylan to form Viatris Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 75 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2011
U.S. locations: 34
States / cities: Phoenix, Arizona • Fayetteville, Arkansas • Fullerton, California + 29 more

Conditions: Anxiety Disorder, Seizures, Epilepsy, Partial Epilepsy, Depression
Interventions: Buspirone, Placebo; Drug
Lead sponsor: National Institute of Neurological Disorders and Stroke (NINDS); NIH
Eligibility: 18 Years to 65 Years
Enrollment: 9 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2016
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Epilepsy
Interventions: Keppra XR (Levetiracetam XR); Drug
Lead sponsor: UCB Pharma; Industry
Eligibility: 12 Years to 75 Years
Enrollment: 190 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2010
U.S. locations: 16
States / cities: Dothan, Alabama • Northport, Alabama • Phoenix, Arizona + 13 more

Conditions: Partial Seizure Disorder
Interventions: Divalproex Sodium (Depakote® Sprinkle Capsules); Drug
Lead sponsor: Abbott; Industry
Eligibility: 3 Years to 10 Years
Enrollment: 300 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2003
U.S. locations: 7
States / cities: Tampa, Florida • Cleveland, Ohio • Columbus, Ohio + 3 more

Conditions: Epilepsy, Complex Partial
Interventions: Zonisamide; Drug
Lead sponsor: Eisai Inc.; Industry
Eligibility: 16 Years and older
Enrollment: 165 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2004
U.S. locations: 25
States / cities: Birmingham, Alabama • Huntsville, Alabama • Northport, Alabama + 22 more

Conditions: Seizures, Seizures, Focal, Seizure, Partial Onset, Seizure Disorder, Partial, Seizure, Partial, Epilepsies, Partial, Epilepsy
Interventions: Zonisamide Oral Product; Drug
Lead sponsor: Azurity Pharmaceuticals; Industry
Eligibility: 1 Month to 17 Years
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 2
States / cities: Winston-Salem, North Carolina • Memphis, Tennessee

Conditions: Transformed Migraine, Chronic Daily Headache
Interventions: SPG Block with 5% Lidocaine gel, Amitriptyline; Procedure · Drug
Lead sponsor: Rutgers, The State University of New Jersey; Other
Eligibility: 18 Years and older
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2020
U.S. locations: 1
States / cities: New Brunswick, New Jersey

Conditions: Partial Seizures
Interventions: Divalproex Sodium (Depakote Sprinkle Capsules); Drug
Lead sponsor: Abbott; Industry
Eligibility: 3 Years to 10 Years
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2005
U.S. locations: 10
States / cities: Northport, Alabama • Phoenix, Arizona • Tampa, Florida + 7 more

Conditions: Seizure Disorder, Partial
Interventions: Pregabalin; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 12 Years and older
Enrollment: 750 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1999 – 2005
U.S. locations: 97
States / cities: Phoenix, Arizona • Tucson, Arizona • Bakersfield, California + 71 more

Conditions: Epilepsies, Partial
Interventions: Vagus Nerve Stimulation Therapy; Device
Lead sponsor: Cyberonics, Inc.; Industry
Eligibility: 12 Years and older
Enrollment: 360 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2007
U.S. locations: 23
States / cities: Phoenix, Arizona • Sun City, Arizona • Los Angeles, California + 19 more

Conditions: Drug-Resistant Epilepsy, Focal-Onset Seizures
Interventions: Padsevonil; Drug
Lead sponsor: UCB Biopharma SRL; Industry
Eligibility: 18 Years and older
Enrollment: 406 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 25
States / cities: Chandler, Arizona • La Jolla, California • San Francisco, California + 21 more

Conditions: Partial Onset Seizures
Interventions: BGG492, Placebo; Drug
Lead sponsor: Novartis; Industry
Eligibility: 18 Years to 65 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2010
U.S. locations: 3
States / cities: Mobile, Alabama • Baltimore, Maryland • Milwaukee, Wisconsin

Conditions: Partial Seizures With Secondary Generalization, Focal Epilepsy With Secondary Generalization
Interventions: High Intensity Focused Ultrasound; Device
Lead sponsor: University of North Carolina, Chapel Hill; Other
Eligibility: 18 Years to 65 Years
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2028
U.S. locations: 1
States / cities: Chapel Hill, North Carolina

Conditions: Focal Onset Seizures
Interventions: SPN-817, Placebo; Drug
Lead sponsor: Supernus Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 216 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 39
States / cities: Phoenix, Arizona • Tucson, Arizona • Little Rock, Arkansas + 33 more

Conditions: Epilepsy
Interventions: ezogabine/retigabine; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 12 Years to 17 Years
Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2013
U.S. locations: 4
States / cities: Los Angeles, California • Wellington, Florida • Memphis, Tennessee + 1 more

Conditions: Seizure Disorder, Partial
Interventions: Pregabalin; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 455 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1998 – 2005
U.S. locations: 48
States / cities: Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 33 more

Conditions: Epilepsy, Seizure Disorders
Interventions: Trigeminal Nerve Stimulation; Device
Lead sponsor: Olive View-UCLA Education & Research Institute; Other
Eligibility: 18 Years to 70 Years
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2011
U.S. locations: 2
States / cities: Los Angeles, California • Sylmar, California

Conditions: Focal Seizures
Interventions: CBD-OS; Drug
Lead sponsor: Jazz Pharmaceuticals; Industry
Eligibility: 12 Years to 75 Years
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 24
States / cities: Phoenix, Arizona • La Jolla, California • New Haven, Connecticut + 20 more

Conditions: Epilepsy
Interventions: retigabine/ezogabine; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 12 Years to 29 Years
Enrollment: 4 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2013
U.S. locations: 4
States / cities: Los Angeles, California • Wellington, Florida • Memphis, Tennessee + 1 more

Conditions: Partial Onset Seizures
Interventions: BGG492; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years to 66 Years
Enrollment: 56 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2012
U.S. locations: 3
States / cities: Tallahassee, Florida • Hamilton, New Jersey • Dallas, Texas

Conditions: Epilepsy
Interventions: Phenobarbital, Placebo tablet; Drug
Lead sponsor: West-Ward Pharmaceutical; Industry
Eligibility: 17 Years to 70 Years
Enrollment: 314 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2016
U.S. locations: 2
States / cities: Lexington, Kentucky • Oklahoma City, Oklahoma

Conditions: Focal Epilepsy
Interventions: BHV-7000, Placebo; Drug
Lead sponsor: Biohaven Therapeutics Ltd.; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 390 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 50
States / cities: Peoria, Arizona • Phoenix, Arizona • Little Rock, Arkansas + 41 more

Search by objective public record fields.

Conversion To Monotherapy With Lamictal Extended Release Tablets For Treatment Of Partial Epilepsy

To Evaluate The Efficacy and Safety of E2007 (Perampanel) Given as Adjunctive Therapy in Subjects With Refractory Partial Seizures

Extension Study Of Long-Term Safety And Efficacy Of Pregabalin As Monotherapy (Lyrica) In Patients With Partial Seizures

Buspirone Therapy for Localized Epilepsy

Long Term Follow-up Study With Keppra XR (Levetiracetam XR) for Partial Seizures

A Study of the Safety and Efficacy of Depakote Sprinkle Capsules in the Treatment of Partial Seizures in Children

Dose Response Study of Zonegran in Patients With Newly Diagnosed Epilepsy

Study of the Pharmacokinetics, Safety, and Tolerability of ZONISADE in Children 1 Month to 17 Years of Age With Partial-onset Seizures

Sphenopalatine Ganglion Nerve Block vs. Elavil for Treatment of Transformed Migraines

A Study for Treatment of Partial Seizures in Children

To Evaluate the Long-Term Safety and Efficacy of Pregabalin in Patients With Partial Seizures.

Effectiveness Study Comparing Treatment With Drug(s) or Adjunctive VNS Therapy for Pharmacoresistant Partial Seizures

Study to Test the Safety and Efficacy of Padsevonil as Adjunctive Treatment of Focal-onset Seizures in Adult Subjects With Drug-resistant Epilepsy

Evaluate the Efficacy of BGG492 as Adjunctive Treatment in Patients With Refractory Partial Onset Seizures

A Pilot Study: Focused Ultrasound Thalamotomy for the Prevention of Secondary Generalization in Focal Onset Epilepsy

RENAISSANCE 2: SPN-817 Phase 2, Double-Blind, Placebo-Controlled Study in Adults With Focal Onset Seizures

Study in Pediatric Subjects With Epilepsy

To Evaluate the Long-Term Safety and Efficacy of Pregabalin in Patients With Partial Seizures

External Trigeminal Nerve Stimulation for Epilepsy

A Study to Evaluate the Efficacy and Safety of Cannabidiol Oral Solution (CBD-OS [GWP42003-P, JZP926]) for the Treatment of Focal-Onset Seizures

Long-term, Open-label Safety Extension Study of Retigabine/Ezogabine in Pediatric Subjects (>= 12 Years Old) With POS or LGS

Phase II BGG492 Capsule Extension for Partial Epilepsy

Evaluation Phenobarbital as Adjunctive Therapy in Participants With Partial Onset Seizures

Study to Determine if BHV-7000 is Effective and Safe in Adults With Refractory Focal Onset Epilepsy